Cargando…

833. Characteristics and Utilization Patterns of Colistin Compared with Newer Agents in Gram-Negative Infections

BACKGROUND: Colistin has resurfaced in light of Gram-negative (GN) resistance. New antibiotics to treat antibiotic resistant GN infections (eg, ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam [new agents]), have recently been approved but their use vs colistin is unclear. We com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcella, Stephen, Doremus, Casey, Echols, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777506/ http://dx.doi.org/10.1093/ofid/ofaa439.1022

Ejemplares similares

Utilization of Colistin Versus β-Lactam and β-Lactamase Inhibitor Agents in Relation to Acute Kidney Injury in Patients with Severe Gram-Negative Infections
por: Doremus, Casey, et al.
Publicado: (2021)

In Vitro Activity of Newer and Conventional Antimicrobial Agents, Including Fosfomycin and Colistin, against Selected Gram-Negative Bacilli in Kuwait
por: Alfouzan, Wadha, et al.
Publicado: (2018)

Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria
por: Taneja, Neelam, et al.
Publicado: (2016)

1285. Outcomes in Patients with Gram-Negative Bacteremia from Phase 2 and Phase 3 Clinical Trials of Cefiderocol, a Novel Siderophore Cephalosporin
por: Kinoshita, David PatersonDavid PatersonMasahiro, et al.
Publicado: (2020)

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
por: Matsunaga, Yuko, et al.
Publicado: (2020)

Flufenamic Acid, a Promising Agent for the Sensitization of Colistin-Resistant Gram-Negative Bacteria to Colistin
por: Zhang, Yi, et al.
Publicado: (2023)

1252. In Vitro Activity of Cefiderocol Against Metallo-β-Lactamase-Producing Gram-Negative Bacteria Collected in North America and Europe Between 2014 and 2017: SIDERO-WT-2014–2016 Studies
por: Takemura, Miki, et al.
Publicado: (2020)

Parenteral colistin for the treatment of severe infections by multidrug-resistant Gram-negative bacteria
por: Grion, C, et al.
Publicado: (2013)

1734. Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021
por: Kung, Frank H, et al.
Publicado: (2022)

1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
por: Yamano, Yoshinori, et al.
Publicado: (2022)

2433. Evaluation of Meropenem (MEM) in Combination With Colistin (COL) Against Colistin-Resistant Extensively Drug-Resistant (XRD) Gram-Negative Bacteria
por: Singh, Nivedita, et al.
Publicado: (2018)

1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2020)

2163. Risk Factors for Carbapenem-Resistant Gram-Negative Bloodstream Infections (BSI) in U.S. Hospitals (2010–2015)
por: Cai, Bin, et al.
Publicado: (2018)

407. Changes in the Utilization Patterns of Antifungal Agents, Medical cost, and Clinical Outcomes of Candidemia by Healthcare Benefit Expansion to Include Newer Antifungal Agents
por: Choi, Heun, et al.
Publicado: (2018)

833. Interaction between Aspergillus fumigatus and non-tuberculous mycobacteria
por: Namie, Hotaka, et al.
Publicado: (2023)

1349. Global Surveillance of Cefiderocol Against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015
por: Tsuji, Masakatsu, et al.
Publicado: (2018)

Efficacy and safety of colistin in the treatment of infections in the ICU caused by multidrug-resistant Gram-negative organisms
por: Pavleas, J, et al.
Publicado: (2006)

Inhaled ceftazidime and amikacin versus inhaled colistin in the treatment of gram negative ventilator associated pneumonia
por: Nassar, YS, et al.
Publicado: (2015)

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

Colistin monotherapy versus combination of colistin with a β-lactam or rifampicin for the treatment of serious infections in the ICU due to multidrug-resistant Gram-negative bacteria
por: Tsimogianni, A, et al.
Publicado: (2006)

1191. Prevalence and Microbiology of Carbapenem Resistance Among Six Gram-Negative Pathogens in Bloodstream Infections in US Hospitals, 2010–2015
por: Lodise, Thomas P, et al.
Publicado: (2018)

Bloodstream Infection and Gram-Negative Resistance: The Role for Newer Antibiotics
por: Waters, Jessica, et al.
Publicado: (2023)

CCM 83.3
Publicado: (1983)

833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results
por: D’Amico, Ronald, et al.
Publicado: (2021)

In vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates Collected from Urinary Track Source: SIDERO-WT-2014/SIDERO-WT-2015
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

In Vivo Efficacy of Humanized Exposures of Cefiderocol Compared with Cefepime (FEP) and Meropenem (MEM) against Gram-negative Bacteria in a Murine Thigh Model
por: Monogue, Marguerite, et al.
Publicado: (2017)

Colistin in the treatment of infections from multiresistant Gram (-) bacilli
por: Markou, N, et al.
Publicado: (2002)

In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

Synergistic Activity of Colistin in Combination With Resveratrol Against Colistin-Resistant Gram-Negative Pathogens
por: Cannatelli, Antonio, et al.
Publicado: (2018)

Comparative evaluation of the UMIC Colistine kit to assess MIC of colistin of gram-negative rods
por: Bardet, Lucie, et al.
Publicado: (2019)

Synergistic Activity of Colistin Combined With Auranofin Against Colistin-Resistant Gram-Negative Bacteria
por: Feng, Xiaoxuan, et al.
Publicado: (2021)

The Antibacterial Activity of Kaempferol Combined with Colistin against Colistin-Resistant Gram-Negative Bacteria
por: Zhou, Huijing, et al.
Publicado: (2022)

Synergistic Activity of Colistin in Combination with Clofoctol against Colistin Resistant Gram-Negative Pathogens
por: Collalto, Diletta, et al.
Publicado: (2023)

Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates
por: Kontou, Angeliki, et al.
Publicado: (2023)

Efficacy of an intravenous colistin regimen in ventilator-associated pneumonia and bacteraemia due to multiresistant Gram-negative bacteria: preliminary results
por: Frantzeskaki, F, et al.
Publicado: (2006)

P43 In vitro activity of cefiderocol and comparators against Gram-negative pathogens: ARTEMIS study in the UK
por: Wareham, D., et al.
Publicado: (2022)

2388. Efficacy of Humanized Cefiderocol Exposures Over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
por: Stainton, Sean, et al.
Publicado: (2018)

Circumventing colistin resistance by combining colistin and antimicrobial peptides to kill colistin-resistant and multidrug-resistant Gram-negative bacteria
por: Witherell, Kaitlin S., et al.
Publicado: (2020)

Naringenin restores colistin activation against colistin-resistant gram-negative bacteria in vitro and in vivo
por: Xu, Mengxin, et al.
Publicado: (2022)

258. A Comparison of Cefprozil and Fluoroquinolones for Gram-Negative Bacteremia
por: Nolen, Rebecca C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vce5a8fhev5b5ha9veqpm9vm2u